IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
University of Washingtonmonoclonal_antibodyPhase 2Active
B
61/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 81/ 100
Competitive context
26 Active assets in the B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
METHOTREXATE OHSU Knight Cancer Institute | Phase 2 | B |
PREDNISONE TABLETS University of Washington | Phase 2 | B |
Blinatumomab OHSU Knight Cancer Institute | Phase 2 | B |
Cyclophosphamide University of Washington | Phase 2 | B |
MERCAPTOPURINE ANHYDROUS National Cancer Institute (NCI) | Phase 2 | B |
View all 29 →
Same molecule, other indications
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →